Majority of younger patients dying of cancer use aggressive interventions in last month of life
the ONA take:
According to a recent study published in JAMA Oncology, researchers at Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Kaiser Permanente Southern California have found that more than two-thirds of adolescents and young adults dying as a result of cancer underwent at least one aggressive intervention during the last month of life.
For the study, researchers evaluated the use of intensive care, the emergency room, chemotherapy, and/or hospitalization in the last month of life in 633 patients aged 15 to 39 years who died of cancer between 2001 and 2010.
Results showed that young patients were more than two times as likely as patients 65 and older to receive intensive care and/or use the emergency room during the last month of life. The rate of use of chemotherapy and hospitalization was similar among both age groups. Researchers found that 22% of the adolescents and young adults used intensive care and/or the emergency room in the last month of life, 11% received chemotherapy in the last two weeks of life, and 62% were hospitalized in the last month of life.
The findings suggest that further research is warranted to determine whether younger patients dying of cancer have been adequately supported to make their end-of-life decisions.
More than two-thirds of adolescents and young adults dying as a result of cancer underwent at least one aggressive intervention during the last month of life.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|